Perimenopause and ADHD: Why Symptoms Worsen and What Helps

Perimenopause is the largest single hormonal shift in adult women's lives, and for many women with ADHD it is the time when symptoms worsen markedly, when previously workable strategies stop working, and when the diagnosis often gets made for the first time. This piece covers what is happening biologically, what the clinical picture usually looks like, what HRT can and cannot do, and what conversations to have with which clinicians.

What is happening biologically

Perimenopause is the transition from regular cycling to menopause, typically running from the mid-forties to early fifties but starting earlier in some women. The hallmark is fluctuating then declining oestrogen, with progressively less predictable cycles, longer or heavier or lighter periods, missed periods, and the gradual emergence of vasomotor symptoms (hot flushes, night sweats), sleep disruption, mood change and cognitive symptoms.

Oestrogen modulates dopamine signalling directly. In the regular cycle, the late-luteal oestrogen drop produces a measurable week of dopamine-related symptom worsening (covered in our ADHD and the menstrual cycle piece). In perimenopause, the same mechanism scales up: declining baseline oestrogen means declining baseline dopamine signalling, on top of an ADHD system that was already running below the general-population baseline ^{[1, 3]}.

The Camara 2022 systematic review in Archives of Women's Mental Health is the cleanest single summary of the relationship between sex hormones, reproductive stages and ADHD across the lifespan ^[1]. The de Jong 2024 qualitative study in Frontiers in Psychiatry covers the lived experience of menopausal symptoms in women with ADHD in detail and confirms the pattern that is now widely reported clinically ^[2].

The clinical picture

What women with ADHD commonly describe in perimenopause:

• Sharp worsening of attention, working memory and executive function. Previously workable strategies (lists, calendars, time-blocking, the productivity apps that have held the working week together) start to fail. Tasks that were difficult become much harder. Cognitive load that was sustainable becomes overwhelming.
• Emotional reactivity goes up. Rejection sensitivity intensifies. Mood becomes more labile. The week-to-week variation seen in the regular cycle gets longer and less predictable.
• Sleep fragments. Vasomotor symptoms, anxiety and ADHD-related sleep difficulty interact. The week of bad sleep has knock-on effects on cognition that compound the underlying perimenopausal effect.
• Burnout patterns. Many women describe perimenopause as the time they hit a wall they cannot work through, even with the strategies that worked for decades.
• First-time diagnosis in many women. A meaningful proportion of women diagnosed with ADHD in midlife report that the perimenopausal worsening is what made the underlying picture impossible to ignore. The Camara 2022 review notes this clinical observation explicitly ^[1].

The pattern is real, biological, and treatable. It is not failure, getting old, or burnout in the personal-fault sense.

How perimenopause is mistaken for stress or burnout

A common pattern: a woman in her mid-to-late forties presents to her GP with worsening attention, mood and cognitive symptoms. The conversation reaches "you're under a lot of stress" or "this might be early menopause, here are some lifestyle suggestions". The ADHD picture is not on the table because it has not been recognised yet; the perimenopause picture is not specifically treated.

The Young 2020 BMC Psychiatry expert consensus statement is unambiguous on this: women presenting with new or worsening cognitive and mood symptoms in midlife should be assessed for ADHD as well as for perimenopause, and the two diagnoses are commonly missed in the same person ^[4]. Treating the perimenopause without recognising the ADHD often produces partial improvement. Treating the ADHD without addressing the perimenopause produces the same.

The HRT conversation

Hormone replacement therapy (HRT) is licensed for the management of menopausal symptoms in the UK. It is well-evidenced for vasomotor symptoms and for the cognitive and mood symptoms of perimenopause. NICE NG23 and the British Menopause Society guidance are the UK clinical references ^{[5, 6]}.

For women with ADHD specifically, the clinical observation (not yet RCT-supported) is that HRT often produces meaningful improvement in the perimenopausal ADHD picture, because restoring oestrogen restores some of the dopamine signalling that was lost. Many women describe a return of their pre-perimenopausal baseline cognition on HRT.

The HRT conversation in the UK runs through the GP, with referral to a specialist menopause clinician where the picture is complex. The decision involves a personal cardiovascular risk assessment, family breast cancer history, contraindications, and personal preference. NICE NG23 covers the framework; the BMS has helpful consensus statements on cognitive symptoms specifically.

A few practical points for women with ADHD considering HRT:

• HRT is not a substitute for ADHD treatment. Where ADHD treatment is indicated, HRT works alongside it, not instead of it.
• The cognitive benefit usually takes weeks, not days. Patience helps.
• The dosing and formulation matter. Transdermal oestrogen (patches, gels, sprays) and micronised progesterone are the BMS-preferred formulations for most women; ask explicitly about these. Older formulations and routes have different risk and side-effect profiles.

ADHD medication adjustments

Many women with ADHD on stimulant treatment find that their previous dose becomes less effective during perimenopause. The mechanism mirrors the late-luteal cycle picture, scaled up: less endogenous oestrogen means less endogenous dopamine modulation, and the medication is working against a lower baseline.

The de Jong 2024 paper describes the clinical practice of upward dose adjustment in perimenopause as one approach, parallel to the premenstrual dose adjustment described elsewhere in this category ^[2]. As with the cycle-specific adjustment, this is a conversation for the prescribing clinician, not something to attempt independently. NICE NG87 does not currently address perimenopause-specific dosing explicitly; the conversation is on the basis of clinical judgement and the developing literature.

What helps

A few things consistently land in the perimenopausal-ADHD picture:

• Get the ADHD picture formally recognised if it has not been. Late midlife diagnosis is common and the assessment is worth pursuing. NeuroFX offers adult ADHD assessment for women specifically.
• Have the HRT conversation with your GP if you are in perimenopause. Bring the cognitive and mood symptoms into the consultation explicitly, not just the hot flushes and sleep.
• Review ADHD medication with your prescribing clinician if the previously effective dose is no longer landing.
• Sleep, exercise and stress management matter more in perimenopause than at other life stages because the underlying biology is offering less margin.
• Patience with the timeline. Perimenopause runs over years, not months. The right HRT, the right ADHD medication and the right load management are usually iterative, not one-shot fixes.

What this means in practice

• Perimenopause involves a declining oestrogen baseline that scales up the menstrual-cycle dopamine effect. Women with ADHD commonly experience marked worsening of attention, mood, sleep and executive function.
• The pattern is biological and treatable, not personal failure or burnout in the fault sense.
• First-time ADHD diagnosis in midlife is common because perimenopausal worsening makes a longstanding underlying picture impossible to ignore.
• HRT (NICE NG23, BMS guidance) often produces meaningful improvement in the perimenopausal ADHD picture; transdermal oestrogen and micronised progesterone are the preferred formulations.
• ADHD medication may need upward adjustment during perimenopause; this is a clinician conversation, not a self-adjustment.
• Recognition and treatment of both the perimenopause and the ADHD together usually goes better than treating either alone.

When to speak to a professional

Speak to your GP if you are in perimenopause with worsening cognitive, mood or sleep symptoms; ask about HRT specifically and reference NICE NG23 if useful. Speak to your prescribing clinician about ADHD medication if your previously effective dose is no longer landing. For first-time ADHD assessment in midlife, NeuroFX offers adult ADHD assessment for women where the NHS wait is not workable. For acute mental health crisis at any point, Samaritans 116 123, NHS 111 mental health option, or 999 / A&E for immediate risk.

Sources

1. Camara B, Padoin C, Bolea B. Relationship between sex hormones, reproductive stages and ADHD: a systematic review. Archives of Women's Mental Health. 2022;25(1):1-8.
2. de Jong M, Wynchank DSMR, Michielsen M, Beekman ATF, Kooij JJS. A qualitative study on the impact of menopausal symptoms in women with ADHD. Frontiers in Psychiatry. 2024;15:1366611.
3. Roberts B, Eisenlohr-Moul T, Martel MM. Reproductive steroids and ADHD symptoms across the menstrual cycle. Psychoneuroendocrinology. 2018;88:105-114.
4. Young S, Adamo N, Asgeirsdottir BB, et al. Females with ADHD: an expert consensus statement taking a lifespan approach. BMC Psychiatry. 2020;20:404.
5. NICE. Menopause: diagnosis and management. NG23. https://www.nice.org.uk/guidance/ng23
6. British Menopause Society. Consensus statements and clinical guidance. https://thebms.org.uk/
7. Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews. 2021;128:789-818.